{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:24:38Z","timestamp":1785795878972,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.7759\/cureus.48160","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T14:29:39Z","timestamp":1698935379000},"source":"Crossref","is-referenced-by-count":7,"title":["A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine"],"prefix":"10.7759","author":[{"given":"Ibrahim M","family":"Dighriri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad","family":"Nazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeshah M","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen A","family":"Altowairqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqeel M","family":"Albariqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A","family":"Tohari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheer A","family":"Alameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad K","family":"Alsaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares R","family":"ALshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif F","family":"AlMutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad M","family":"Alsubaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki A","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5","article-title":"European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco S","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, et al.. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020, 21:76. 10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"key":"ref2","article-title":"","author":"Pescador Ruschel MA","year":"2023","unstructured":"Pescador Ruschel MA, De Jesus O. Migraine Headache. StatPearls Publishing, Treasure Island, FL; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560787\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch RC","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019, 37:631-49. 10.1016\/j.ncl.2019.06.001","journal-title":"Neurol Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019","volume":"163","author":"Safiri S","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, et al.. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022, 163:e293-309. 10.1097\/j.pain.0000000000002275","journal-title":"Pain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner TJ","year":"2023","unstructured":"Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023, 19:109-17. 10.1038\/s41582-022-00763-1","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.32628\/IJSRST229399","article-title":"Migraine: evolution of a common disorder","volume":"9","author":"Chaudhary R","year":"2022","unstructured":"Chaudhary R, Saini R, Rawat RS, Bachhas R, Majani R, Arya MH. Migraine: evolution of a common disorder. Int J Sci Res Sci Technol. 2022, 9:520-9. 10.32628\/IJSRST229399","journal-title":"Int J Sci Res Sci Technol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-1","article-title":"Migraine: the seventh disabler","volume":"14","author":"Steiner TJ","year":"2013","unstructured":"Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013, 14:1. 10.1186\/1129-2377-14-1","journal-title":"J Headache Pain"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa7557","article-title":"Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine","volume":"7","author":"Akerman S","year":"2015","unstructured":"Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015, 7:308ra157. 10.1126\/scitranslmed.aaa7557","journal-title":"Sci Transl Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1231897","article-title":"Spreading depression triggers headache by activating neuronal Panx1 channels","volume":"339","author":"Karatas H","year":"2013","unstructured":"Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Ko\u00e7ak E, Sen ZD, Dalkara T. Spreading depression triggers headache by activating neuronal Panx1 channels. Science. 2013, 339:1092-5. 10.1126\/science.1231897","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000010861","article-title":"Therapeutic options for migraines in the microsurgical patient: a scoping review. [PREPRINT]","author":"Stearns SA","year":"2023","unstructured":"Stearns SA, Xun H, Haddad A, Rinkinen J, Bustos VP, Lee BT. Therapeutic options for migraines in the microsurgical patient: a scoping review. [PREPRINT]. Plast Reconstr Surg. 2023, 10.1097\/PRS.0000000000010861","journal-title":"Plast Reconstr Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00418-y","article-title":"Management of chronic migraine in children and adolescents: a brief discussion on preventive therapies","volume":"22","author":"Kacperski J","year":"2020","unstructured":"Kacperski J, Green A, Qaiser S. Management of chronic migraine in children and adolescents: a brief discussion on preventive therapies. Paediatr Drugs. 2020, 22:635-43. 10.1007\/s40272-020-00418-y","journal-title":"Paediatr Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/head.12640","article-title":"Systematic review of preventive and acute treatment of menstrual migraine","volume":"55","author":"Nierenburg Hdel C","year":"2015","unstructured":"Nierenburg Hdel C, Ailani J, Malloy M, Siavoshi S, Hu NN, Yusuf N. Systematic review of preventive and acute treatment of menstrual migraine. Headache. 2015, 55:1052-71. 10.1111\/head.12640","journal-title":"Headache"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019, 59:1-18. 10.1111\/head.13456","journal-title":"Headache"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413508661","article-title":"Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis","volume":"34","author":"Thorlund K","year":"2014","unstructured":"Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, Goadsby PJ. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014, 34:258-67. 10.1177\/0333102413508661","journal-title":"Cephalalgia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01494-9","article-title":"Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review","volume":"37","author":"Leroux E","year":"2020","unstructured":"Leroux E, Buchanan A, Lombard L, et al.. Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020, 37:4765-96. 10.1007\/s12325-020-01494-9","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000001194","article-title":"Anatomical regional targeted (ART) BOTOX injection technique: a novel paradigm for migraines and chronic headaches","volume":"4","author":"Amirlak B","year":"2016","unstructured":"Amirlak B, Sanniec K, Pezeshk R, Chung M. Anatomical regional targeted (ART) BOTOX injection technique: a novel paradigm for migraines and chronic headaches. Plast Reconstr Surg Glob Open. 2016, 4:e1194. 10.1097\/GOX.0000000000001194","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/TME.0000000000000319","article-title":"Valproic acid in the treatment of migraines","volume":"42","author":"Brown BL","year":"2020","unstructured":"Brown BL, Craycraft LK, Justice SB. Valproic acid in the treatment of migraines. Adv Emerg Nurs J. 2020, 42:243-53. 10.1097\/TME.0000000000000319","journal-title":"Adv Emerg Nurs J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419884943","article-title":"Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries","volume":"40","author":"Rubio-Beltran E","year":"2020","unstructured":"Rubio-Beltran E, Chan KY, Danser AJ, MaassenVanDenBrink A, Edvinsson L. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2020, 40:357-66. 10.1177\/0333102419884943","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081075","article-title":"Blocking the CGRP receptor: differences across human vascular beds","volume":"16","author":"de Vries T","year":"2023","unstructured":"de Vries T, Boucherie DM, van den Bogaerdt A, Danser AH, MaassenVanDenBrink A. Blocking the CGRP receptor: differences across human vascular beds. Pharmaceuticals (Basel). 2023, 16:1075. 10.3390\/ph16081075","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00234-7","article-title":"Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials","volume":"10","author":"Hutchinson S","year":"2021","unstructured":"Hutchinson S, Dodick DW, Treppendahl C, Bennett NL, Yu SY, Guo H, Trugman JM. Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther. 2021, 10:235-49. 10.1007\/s40120-021-00234-7","journal-title":"Neurol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231151419","article-title":"Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature","volume":"43","author":"Puledda F","year":"2023","unstructured":"Puledda F, Younis S, Huessler EM, Haghdoost F, Lisicki M, Goadsby PJ, Tassorelli C. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia. 2023, 43:10.1177\/03331024231151419","journal-title":"Cephalalgia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-019-0768-y","article-title":"CGRP antagonists for the treatment of chronic migraines: a comprehensive review","volume":"23","author":"Urits I","year":"2019","unstructured":"Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, Viswanath O. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep. 2019, 23:29. 10.1007\/s11916-019-0768-y","journal-title":"Curr Pain Headache Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211000311","article-title":"Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II","volume":"41","author":"Hutchinson S","year":"2021","unstructured":"Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021, 41:979-90. 10.1177\/03331024211000311","journal-title":"Cephalalgia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221144784","article-title":"New migraine drugs","volume":"43","author":"Puledda F","year":"2023","unstructured":"Puledda F, Tassorelli C, Diener HC. New migraine drugs. Cephalalgia. 2023, 43:10.1177\/03331024221144784","journal-title":"Cephalalgia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S244249","article-title":"Ubrogepant in the acute management of migraine: a narrative review","volume":"14","author":"Chiang CC","year":"2021","unstructured":"Chiang CC, VanderPluym JH. Ubrogepant in the acute management of migraine: a narrative review. J Pain Res. 2021, 14:1185-92. 10.2147\/JPR.S244249","journal-title":"J Pain Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick DW","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the treatment of migraine. N Engl J Med. 2019, 381:2230-41. 10.1056\/NEJMoa1813049","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420983282","article-title":"Migraine therapeutics differentially modulate the CGRP pathway","volume":"41","author":"Bhakta M","year":"2021","unstructured":"Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD. Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia. 2021, 41:499-514. 10.1177\/0333102420983282","journal-title":"Cephalalgia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.085670","article-title":"Continuum of host-gut microbial co-metabolism: host CYP3A4\/3A7 are responsible for tertiary oxidations of deoxycholate species","volume":"47","author":"Zhang J","year":"2019","unstructured":"Zhang J, Gao LZ, Chen YJ, et al.. Continuum of host-gut microbial co-metabolism: host CYP3A4\/3A7 are responsible for tertiary oxidations of deoxycholate species. Drug Metab Dispos. 2019, 47:283-94. 10.1124\/dmd.118.085670","journal-title":"Drug Metab Dispos"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211014625","article-title":"Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance","volume":"41","author":"Tfelt-Hansen P","year":"2021","unstructured":"Tfelt-Hansen P, H\u00fcsing A, Diener HC. Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance. Cephalalgia. 2021, 41:1276-8. 10.1177\/03331024211014625","journal-title":"Cephalalgia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420970523","article-title":"Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications","volume":"41","author":"Goadsby PJ","year":"2021","unstructured":"Goadsby PJ, Blumenfeld AM, Lipton RB, et al.. Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications. Cephalalgia. 2021, 41:546-60. 10.1177\/0333102420970523","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1066","article-title":"Single-dose pharmacokinetics and safety of ubrogepant in adults with hepatic impairment: results from an open-label, phase 1 trial","volume":"11","author":"Boinpally R","year":"2022","unstructured":"Boinpally R, Lu K. Single-dose pharmacokinetics and safety of ubrogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev. 2022, 11:857-64. 10.1002\/cpdd.1066","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201031","article-title":"Efficacy of ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain","volume":"99","author":"Lipton RB","year":"2022","unstructured":"Lipton RB, Dodick DW, Goadsby PJ, et al.. Efficacy of ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain. Neurology. 2022, 99:e1905-15. 10.1212\/WNL.0000000000201031","journal-title":"Neurology"},{"key":"ref33","article-title":"Emerging therapies for patients with difficult-to-treat migraine","volume":"43","author":"Kish T","year":"2018","unstructured":"Kish T. Emerging therapies for patients with difficult-to-treat migraine. P T. 2018, 43:616-21.","journal-title":"P T"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13506","article-title":"Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice","volume":"292","author":"Edvinsson L","year":"2022","unstructured":"Edvinsson L. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice. J Intern Med. 2022, 292:575-86. 10.1111\/joim.13506","journal-title":"J Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients - a review of pros and cons","volume":"18","author":"Deen M","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, et al.. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017, 18:96. 10.1186\/s10194-017-0807-1","journal-title":"J Headache Pain"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221137092","article-title":"Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks","volume":"43","author":"Begasse de Dhaem O","year":"2023","unstructured":"Begasse de Dhaem O, Takizawa T, Dodick DW. Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. Cephalalgia. 2023, 43:10.1177\/03331024221137092","journal-title":"Cephalalgia"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.30629\/2658-7947-2022-27-3-5-10","article-title":"Relief of migraine attack \u2014 hepants","volume":"27","author":"Yadgarov IS","year":"2022","unstructured":"Yadgarov IS, Filatova EG, Golubev VL, Berdnikova A V. Relief of migraine attack \u2014 hepants. Russ Neurol J. 2022, 27:5-10. 10.30629\/2658-7947-2022-27-3-5-10","journal-title":"Russ Neurol J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13027","article-title":"miR-34a-5p up-regulates the IL-1\u03b2\/COX2\/PGE2 inflammation pathway and induces the release of CGRP via inhibition of SIRT1 in rat trigeminal ganglion neurons","volume":"11","author":"Zhang H","year":"2021","unstructured":"Zhang H, Zhang XM, Zong DD, Ji XY, Jiang H, Zhang FZ, He SD. miR-34a-5p up-regulates the IL-1\u03b2\/COX2\/PGE2 inflammation pathway and induces the release of CGRP via inhibition of SIRT1 in rat trigeminal ganglion neurons. FEBS Open Bio. 2021, 11:300-11. 10.1002\/2211-5463.13027","journal-title":"FEBS Open Bio"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025998118","article-title":"PIP2 corrects cerebral blood flow deficits in small vessel disease by rescuing capillary Kir2.1 activity","volume":"118","author":"Dabertrand F","year":"2021","unstructured":"Dabertrand F, Harraz OF, Koide M, et al.. PIP2 corrects cerebral blood flow deficits in small vessel disease by rescuing capillary Kir2.1 activity. Proc Natl Acad Sci U S A. 2021, 118:e2025998118. 10.1073\/pnas.2025998118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton RB","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019, 322:1887-98. 10.1001\/jama.2019.16711","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss T","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW, et al.. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016, 36:887-98. 10.1177\/0333102416653233","journal-title":"Cephalalgia"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000001072","article-title":"Rimegepant, ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat\/harm","volume":"38","author":"Johnston KM","year":"2022","unstructured":"Johnston KM, Powell L, Popoff E, Harris L, Croop R, Coric V, L'Italien G. Rimegepant, ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat\/harm. Clin J Pain. 2022, 38:680-5. 10.1097\/AJP.0000000000001072","journal-title":"Clin J Pain"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","article-title":"Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis","volume":"4","author":"Yang CP","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM, et al.. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021, 4:e2128544. 10.1001\/jamanetworkopen.2021.28544","journal-title":"JAMA Netw Open"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: a narrative review","volume":"20","author":"Agostoni EC","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, et al.. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019, 20:92. 10.1186\/s10194-019-1038-4","journal-title":"J Headache Pain"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.06.003","article-title":"CGRP and migraine: from bench to bedside","volume":"177","author":"Edvinsson L","year":"2021","unstructured":"Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021, 177:785-90. 10.1016\/j.neurol.2021.06.003","journal-title":"Rev Neurol (Paris)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: new drugs, new hope?","volume":"20","author":"Do TP","year":"2019","unstructured":"Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope?. J Headache Pain. 2019, 20:37. 10.1186\/s10194-019-0974-3","journal-title":"J Headache Pain"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00135","article-title":"To probe the binding interactions between two FDA approved migraine drugs (ubrogepant and rimegepant) and calcitonin-gene related peptide receptor (CGRPR) using molecular dynamics simulations","volume":"12","author":"Leung L","year":"2021","unstructured":"Leung L, Liao S, Wu C. To probe the binding interactions between two FDA approved migraine drugs (ubrogepant and rimegepant) and calcitonin-gene related peptide receptor (CGRPR) using molecular dynamics simulations. ACS Chem Neurosci. 2021, 12:2629-42. 10.1021\/acschemneuro.1c00135","journal-title":"ACS Chem Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: first approval","volume":"80","author":"Scott LJ","year":"2020","unstructured":"Scott LJ. Ubrogepant: first approval. Drugs. 2020, 80:323-8. 10.1007\/s40265-020-01264-5","journal-title":"Drugs"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1945444","article-title":"Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis","volume":"22","author":"Johnston K","year":"2022","unstructured":"Johnston K, Popoff E, Deighton A, et al.. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2022, 22:155-66. 10.1080\/14737167.2021.1945444","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211023810","article-title":"Ubrogepant: an oral calcitonin gene-related peptide (CGRP) receptor antagonist for abortive migraine treatment","volume":"56","author":"Nedd M","year":"2022","unstructured":"Nedd M, Garland S, Falk N, Wilk A. Ubrogepant: an oral calcitonin gene-related peptide (CGRP) receptor antagonist for abortive migraine treatment. Ann Pharmacother. 2022, 56:346-51. 10.1177\/10600280211023810","journal-title":"Ann Pharmacother"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1021","article-title":"Population PK analyses of ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling","volume":"58","author":"Li CC","year":"2018","unstructured":"Li CC, Dockendorf M, Kowalski K, et al.. Population PK analyses of ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling. J Clin Pharmacol. 2018, 58:294-303. 10.1002\/jcph.1021","journal-title":"J Clin Pharmacol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024741","article-title":"Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: a meta-analysis","volume":"100","author":"Zhang Z","year":"2021","unstructured":"Zhang Z, Shu Y, Diao Y, Du Y, Chen L, Liu Y, Du B. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: a meta-analysis. Medicine (Baltimore). 2021, 100:e24741. 10.1097\/MD.0000000000024741","journal-title":"Medicine (Baltimore)"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/head.13379","article-title":"History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment","volume":"58","author":"Tepper SJ","year":"2018","unstructured":"Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018, 58:238-75. 10.1111\/head.13379","journal-title":"Headache"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S132833","article-title":"Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential","volume":"11","author":"Negro A","year":"2018","unstructured":"Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018, 11:515-26. 10.2147\/JPR.S132833","journal-title":"J Pain Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53717-1.01601-2","article-title":"Triptans","author":"Aronson JK","year":"2016","unstructured":"Aronson JK. Triptans. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Aronson JK (ed): Elsevier, Amsterdam, Netherlands; 2016. 205-10. 10.1016\/B978-0-444-53717-1.01601-2"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1288721","article-title":"Triptans and migraine: advances in use, administration, formulation, and development","volume":"18","author":"Macone AE","year":"2017","unstructured":"Macone AE, Perloff MD. Triptans and migraine: advances in use, administration, formulation, and development. Expert Opin Pharmacother. 2017, 18:387-97. 10.1080\/14656566.2017.1288721","journal-title":"Expert Opin Pharmacother"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008042.pub3","article-title":"Triptans for acute cluster headache","volume":"2013","author":"Law S","year":"2013","unstructured":"Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2013, 2013:CD008042. 10.1002\/14651858.CD008042.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682","article-title":"Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial","volume":"60","author":"Ailani J","year":"2020","unstructured":"Ailani J, Lipton RB, Hutchinson S, et al.. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020, 60:141-52. 10.1111\/head.13682","journal-title":"Headache"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420915167","article-title":"Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response","volume":"40","author":"Marcus SC","year":"2020","unstructured":"Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN, Doshi JA. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020, 40:639-49. 10.1177\/0333102420915167","journal-title":"Cephalalgia"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2020.06.019","article-title":"Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine\u2014the monoclonal antibodies and gepants","volume":"255","author":"Chiang CC","year":"2020","unstructured":"Chiang CC, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine\u2014the monoclonal antibodies and gepants. Prog Brain Res. 2020, 255:143-70. 10.1016\/bs.pbr.2020.06.019","journal-title":"Prog Brain Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061656","article-title":"New generation gepants: migraine acute and preventive medications","volume":"11","author":"Moreno-Ajona D","year":"2022","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications. J Clin Med. 2022, 11:1656. 10.3390\/jcm11061656","journal-title":"J Clin Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications","volume":"39","author":"Dodick DW","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019, 39:445-58. 10.1177\/0333102418821662","journal-title":"Cephalalgia"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2542","article-title":"Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: a meta-analysis","volume":"12","author":"Huang T","year":"2022","unstructured":"Huang T, Xu Y, Chen Y, Bian J, Chu Z, Zhao S, Ma L. Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: a meta-analysis. Brain Behav. 2022, 12:e2542. 10.1002\/brb3.2542","journal-title":"Brain Behav"},{"key":"ref64","unstructured":"UBRELVY - ubrogepant tablet. (2023). https.\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab."},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfac051","article-title":"Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling","volume":"188","author":"Woodhead JL","year":"2022","unstructured":"Woodhead JL, Siler SQ, Howell BA, Watkins PB, Conway C. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022, 188:108-16. 10.1093\/toxsci\/kfac051","journal-title":"Toxicol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/195781-a-comprehensive-review-of-the-mechanism-efficacy-safety-and-tolerability-of-ubrogepant-in-the-treatment-of-migraine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:31Z","timestamp":1707509311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/195781-a-comprehensive-review-of-the-mechanism-efficacy-safety-and-tolerability-of-ubrogepant-in-the-treatment-of-migraine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":65,"URL":"https:\/\/doi.org\/10.7759\/cureus.48160","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}